Adding local therapy after osimertinib plus chemo for EGFR lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether directly treating the remaining lung tumor with surgery or radiation, after initial chemo and osimertinib, can improve outcomes for people with advanced EGFR-mutant non-small cell lung cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage IV non-small cell lung cancer with an EGFR mutation (exon 19 deletion or L858R).
- You have completed four cycles of osimertinib plus platinum-based chemo as your first treatment.
- Your cancer has shrunk or stayed stable after those cycles.
- The main tumor in your lung can still be treated with surgery or radiation.
- You are age 20 or older, and your daily activity level is good (ECOG 0 or 1).
- You do not have untreated or unstable brain metastases, or another active cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether removing the main lung tumor with surgery and then taking the targeted drug osimertinib helps people with advanced non-small cell lung cancer that has an EGFR mutation. The goal is to see if this approach can improve outcomes compared to just taking the drug alone.
This study tests whether giving osimertinib together with chemotherapy before surgery can shrink and control EGFR-mutant, stage III lung cancer so it can be fully removed. If it works, it may improve the chances that the cancer does not come back after surgery.
This trial tests whether adding a new drug (SYS6010) to the standard targeted therapy osimertinib before surgery can help shrink EGFR-positive lung tumors more than osimertinib alone. It is for people with early-stage (II to IIIB) non-small cell lung cancer that can be removed surgically.
This trial tests a new combination of the drug osimertinib with chemotherapy for people whose lung cancer has returned after they took osimertinib alone following surgery. It aims to see if this combined approach helps control the cancer better.
This study tests whether adding a precise, high-dose type of radiation (called SBRT or SRS) to the targeted therapy pill osimertinib can better control lung cancer that has an EGFR mutation. If you have had a good response to osimertinib but still have a few remaining tumors, this combination may help improve outcomes.
This trial collects data from people with early-stage lung cancer that has a common EGFR mutation. After complete surgical removal of the tumor, participants take osimertinib for 3 years and are followed regularly to see how well the treatment works and why resistance might develop.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.